Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women with Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: a pharmacokinetic study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40795873.
- Also identified by DOI 10.1093/cid/ciaf443.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this breastmilk pharmacokinetic study of women undergoing hepatitis C virus treatment with sofosbuvir/velpatasvir, sofosbuvir, GS-331007 (sofosbuvir metabolite), and velpatasvir concentrations in breast milk were 13%, 1.2%, and 41% of maternal plasma concentrations, respectively. The estimated infant daily dose from breastmilk was <1% of the weight-adjusted dose for children.